GlassScriptPhysician profile
Shanthi Rajendran
NPI 1346378924
$12,583.71
in general payments reported to CMS, 2019-2025
30 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,660 · 2020: $1,485 · 2021: $1,574 · 2022: $1,432 · 2023: $1,798 · 2024: $1,755 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,409 · Education: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,409.27 |
| Education | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,204.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,341.88 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,054.68 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $801.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $800.63 | 2019-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Pfizer INC. | $705.63 | 2019-2025 | |
| Amgen INC. | $660.60 | 2020-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $587.93 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $507.40 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $493.51 | 2023-2025 | Nuzyra, Xhance |
| Corcept Therapeutics | $471.88 | 2024-2025 | Korlym |
| Esperion Therapeutics, INC. | $403.38 | 2020-2025 | Nexletol |
| Allergan, INC. | $339.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $321.62 | 2019-2024 | Verquvo, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $309.53 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $284.50 | 2019-2023 | |
| Exact Sciences Corporation | $269.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $238.79 | 2021 | |
| Glaxosmithkline, LLC. | $195.39 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Mannkind Corporation | $150.02 | 2023 | V-Go, Afrezza |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Abbott Laboratories | $66.89 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Seqirus USA INC | $60.40 | 2025 | Fluad, Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $53.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $50.26 | 2019-2023 | |
| Insulet Corporation | $33.54 | 2024 | Omnipod |
| Abbvie INC. | $22.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.57 | 2024 | Eliquis |
| Axsome Therapeutics, INC. | $20.00 | 2025 | Auvelity |
| Mylan Specialty L.P. | $14.24 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanthi Rajendran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.